DanCann Pharma’s Shares And Warrants Offering


Andersen Partners assisted DanCann Pharma in this transaction.

DanCann Pharma was provided approximately DKK 30 million (before issue costs) in the oversubscribed IPO of units which resulted in more than 1 600 new shareholders.

The total number of shares in DanCann Pharma is 20 730 800 shares and the share capital amount to DKK 777 405. In addition, there are a total of 2 668 000 warrants of series TO 1 issued. Each warrant of series TO 1 entitles the holder the right to subscribe for one new share in DanCann Pharma at a subscription price of DKK 6 per share during the exercise period September 1, 2021 until September 17, 2021.

DanCann Pharma A/S’ public offer was oversubscribed, and the first day of trading in DanCann Pharma A/S shares and warrants on Spotlight Stock Market is today, 12 November 2020.

DanCann Pharma was founded in 2018 and is a Danish pharmaceutical biotechnology company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed cultivation and distribution company based in Denmark. The company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.

The Andersen Partners team included Michael Kristensen, Peter Stanstrup and Hans-Christian Ohr.

Involved fees earner: Michael Kristensen – Andersen Partners; Hans-Christian Ohrt – Andersen Partners; Peter Stanstrup – Andersen Partners;

Law Firms: Andersen Partners;

Clients: DanCann Pharma A/S;

Print Friendly, PDF & Email